Navigation Links
PhRMA CEO John Castellani Responds to Mid-Term Election, Stresses Importance of Innovation to Help Grow Economy
Date:11/3/2010

WASHINGTON, Nov. 3, 2010 /PRNewswire-USNewswire/ -- Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani released the following statement and video regarding the mid-term election:

Watch the Video

"Congratulations to all of the candidates who worked so hard on the campaign trail to earn the trust and votes of the American public.

"Two issues dominated the election this year: the state of our economy and jobs.

"There is no doubt that the last several years have been very tough for America and its workers.

"This is why it's so important for our nation's leaders to recognize the important role that America's biopharmaceutical research companies play in contributing to the national economy and creating millions of U.S. jobs as they develop medical advances.

"One way we can help our economy grow is to ensure that America remains the worldwide hub for scientific and medical research.

"When it comes to medical innovation, our nation is at a crossroads and it's up to our leaders to decide what path they want to take. Do they want to support the innovative engines that fuel America's economy, or do they want to let other countries win the race for knowledge, jobs and growth in the life sciences field?

"We believe the right path is one that strengthens the scientific and economic environments that foster medical advancements and serve as the foundations for great jobs and U.S. global competitiveness.

"Over the last couple of months, people have asked me why I took the job to lead PhRMA. My response is simple: I want to represent the most research-intensive sector in the U.S. Our companies are dedicated to improving and saving the lives of millions of patients worldwide and their work is also vital to our nation's economic prospects.

"I've had the honor of meeting many of the men and women working at biopharmaceutical companies who are researching and developing new medicines that can help patients battle diseases such as cancer, HIV/AIDS, heart disease and Alzheimer's. Collectively and individually, their passion, their ingenuity, their vision and, perhaps most importantly their determination, are resources that can't be taken for granted. They must be preserved and cultivated to reach even greater heights.

"Rest assured, America's biopharmaceutical companies are striving to achieve the next breakthrough. For example, consider Alzheimer's – PhRMA just released a report showing that our companies are working on nearly 100 new medicines for patients battling this devastating disease and related dementias.

"I urge you to check out the personal stories of company researchers, some of whom have inspirational stories about loved ones suffering from Alzheimer's, who are working on future treatments that could hold the key to eliminating the pain caused by this disease and helping to control related health care costs.

"The Alzheimer's Association recently estimated that the development of a new treatment that delays the onset of Alzheimer's could reduce Medicare and Medicaid spending on patients with the disease by more than $100 billion annually by 2030.

"In today's economic climate, we can't afford to ignore these potential savings.

"Congratulations again to our elected officials. We look forward to working with the new Congress on all of these important issues in the months and years ahead."

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $45.8 billion in 2009 in discovering and developing new medicines. Industry-wide research and investment reached a record $65.3 billion in 2009.

PhRMA Internet Address: http://www.phrma.org

For information on how innovative medicines save lives, visit: http://www.innovation.org

For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org

For more information on public health emergencies, visit: http://www.rxresponse.org

For information on the danger of imported drugs, visit: http://www.buysafedrugs.info


'/>"/>
SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PhRMA Statement on Senate Finance Committee Vote
2. PhRMA Statement Supporting Fair Incentives for Biologics Innovation
3. Seven New Biopharmaceutical Research Companies Join PhRMAs Mission to Advance Medical Innovation
4. PhRMA Honors Patient Advocates Ron and Raychel Bartek
5. Pfizers Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts
6. PhRMA Statement on Health Care Reform
7. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
8. Roche responds to announcement of IDEAL hepatitis C trial results
9. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
10. GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition
11. AstraZeneca Responds to FDA Joint Advisory Committees Recommendation on SYMBICORT(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017 Medical information groups within ... their self-service capabilities to manage inquiries from external ... New research from consulting leader Best Practices, ... self-service website portals where HCPs can sign on ... of many findings to emerge from the new ...
(Date:2/24/2017)... ITL Limited, ( ASX: ITD ), ... für das zum 31. Dezember 2016 endende Halbjahr ... vorlegen zu können. Eine vollständige Präsentation „Ergebnisse von ... Sie hier . Glanzpunkte ... 2015: 1,04 Millionen USD; +104 %) Gewinn je ...
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017 ... gives comprehensive insights on the various drugs ... The report covers all the drugs that ... Preclinical & Clinical). The pipeline focuses on ... small molecules, antibodies, stem cell therapies, recombinant ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. Ronald E. Hawkins, ... the appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the ... April 10. Dr. Bell comes to Liberty from the Ohio University Heritage College ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: ... ’s true account of his paramedic experiences. Schanssema describes the tragedies he saw, as ... attempts to overcome them. , Schanssema, initially unsure of the career path he wanted ...
(Date:2/24/2017)... ... 24, 2017 , ... Indiana Fiber Network (IFN) President and CEO Kelly C. ... Dyer started as the Chairman of the Management Committee when IFN was originally formed ... the recruitment of investor/owners and development of the business plan. He became the ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... 2017 partnership with The Jensie Gran Fondo of Marin. For the second year ... with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled to provide our safe, ...
(Date:2/23/2017)... ... , ... The American Cleft Palate-Craniofacial Association (ACPA) is pleased to announce KLS ... longtime supporter of the event. , "We are pleased that KLS Martin is joining ... 2017 ACPA President. "KLS Martin has a long track record of support of the ...
Breaking Medicine News(10 mins):